What Dolgit Treats: Main Uses and Benefits

The primary therapeutic utility of this topical preparation is to provide targeted, symptomatic support for localized pain, stiffness, and inflammation within the musculoskeletal system. It is applied across domains where additional symptomatic support is needed, generally aligning with official therapeutic recommendations for this class of medicine.

Easing Discomfort from Acute Soft Tissue Injuries

This medicine is commonly used across conditions characterized by acute, sudden symptomatic episodes such as sprains, strains, and contusions (blunt injuries). It is relevant in clinical settings marked by heightened distress and pain during the initial recovery phase. The preparation may be part of symptomatic management for distressing symptoms related to localized trauma, including sports injuries and backache. The primary benefit generally provides support that helps ease the overall symptom burden.

The medicine may be applied in conditions presenting with symptoms that interfere with daily functioning, such as local muscle pain, lumbago, tendinitis, bursitis, and localized pain associated with mild arthritic conditions.

“The application is relevant when supportive symptom management is appropriate, especially during phases when localized pain becomes more noticeable.”

Supportive Management for Chronic Joint and Periarticular Conditions

Dolgit is applicable in conditions marked by episodic or fluctuating symptom patterns related to localized mild to moderate arthritic conditions and inflammation of soft tissues surrounding the joints. It is often used during phases when symptoms intensify and supportive relief is needed. This symptomatic assistance contributes to improved comfort during periods of heightened joint discomfort, helping patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Localized Pain and Inflammation

Dolgit is commonly used when short-term symptomatic assistance is needed to address symptoms related to inflammatory or irritative states in muscles and joints, assisting with maintaining functional stability.

Dolgit (topical ibuprofen) eligibility is strictly defined by regulatory authorities based on age, allergy status, and pre-existing health conditions. Use is generally established for adults and adolescents 14 years of age and older.

Eligibility Status

Classification	Defined Regulatory Condition
Absolute Contraindication	Patients with known hypersensitivity to ibuprofen, any excipients, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including aspirin. This extends to individuals with a history of NSAID-induced asthma or rhinitis.
	Children and adolescents under 14 years due to insufficient safety data, and women in the last trimester of pregnancy (after 30 weeks of gestation).
Conditional Use	Use in the first and second trimesters of pregnancy is restricted to medical review of benefits versus risks. Use during lactation is generally permitted for short-term periods, but application to the breast area is prohibited.
Special Caution	Patients with pre-existing conditions such as severe renal impairment, hepatic dysfunction, or cardiac impairment require medical supervision. The medicine must not be applied to damaged skin or under occlusive dressings.

The official eligibility profile establishes clear exclusion criteria for populations at risk of systemic NSAID exposure or allergic reactions, while confirming conditional use for individuals with certain chronic health conditions.

Interactions with Other Medicines and Products

The official regulatory profile for this topical Ibuprofen preparation focuses on managing systemic risks that may be reinforced by combining it with other medicines. The interaction information is derived from documented class warnings for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).

Interaction-Related Restrictions

Classification	Interacting Agents	Official Descriptive Outcome
Contraindicated/Avoided	Oral NSAIDs (including other ibuprofen products)	Co-administration is strongly cautioned against or contraindicated due to the increased risk of gastrointestinal (GI) bleeding and ulceration.
Timing-Sensitive	Aspirin (low-dose, antiplatelet)	Requires specific separation of administration time (e.g., eight hours before or 30 minutes after immediate-release aspirin) to avoid interference with the antiplatelet effect.
Substance Warning	Alcohol (3 drinks daily)	Increases the documented risk of serious GI bleeding associated with NSAID use.

Clinically Significant Interactions

Interactions with the following systemic medications are documented due to pharmacodynamic reinforcement or altered clearance of the co-administered drug:

• Anticoagulants (e.g., Warfarin) and Corticosteroids: Co-administration increases the documented risk of severe bleeding and GI adverse events.
• Antihypertensives (Diuretics, ACE Inhibitors/ARBs): NSAIDs may reduce the blood pressure-lowering and fluid-regulating effects, a risk that is heightened in elderly patients or those with renal impairment, potentially leading to renal function deterioration.
• Lithium and Methotrexate: NSAIDs may decrease the renal clearance of these substances, which can result in increased plasma concentrations and potential toxicity.

The regulatory documents consistently emphasize that these interaction concerns are tied to the systemic presence of Ibuprofen, even following topical administration, and define the necessary constraints for use.

The primary mechanism-of-action of ibuprofen, the active substance in Dolgit, involves its role as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This action occurs at the site of inflammation where it prevents the binding of the substrate, arachidonic acid, to the active site of the enzyme. This type of inhibition is crucial for disrupting the subsequent biochemical cascade.

By inhibiting COX-1 and COX-2 activity, ibuprofen effectively blocks the conversion of arachidonic acid into various prostanoids, including prostaglandins, thromboxanes, and prostacyclins. The resulting reduction in prostaglandin synthesis modulates the cellular signals that propagate the initial inflammatory response. This biochemical change is the mechanistic cascade initiated by the drug’s primary interaction with its enzyme target.

In addition to its anti-inflammatory mechanism, ibuprofen also exerts a reversible inhibitory effect on platelet aggregation. This is achieved through the transient inhibition of COX-1 in platelets, which reduces the production of thromboxane A2 (TXA2). This effect decreases the platelet's ability to respond to stimuli such as ADP and collagen, thereby altering the physiological process of primary hemostasis.

How to Use Dolgit

The application of Dolgit, a topical Ibuprofen preparation, involves specific steps to ensure appropriate dermal use and measured delivery of the active ingredient.

Administration Scope	Property	Instruction
Route of administration	Dermal (Topical use, applied to the skin). Iontophoresis is also an application technique under the cathode.
Dosing schedule	A 4 - 10 cm strip of cream or gel is applied per dose, corresponding to approximately 100 - 250 mg of Ibuprofen. The maximum daily dose does not exceed 600 mg of Ibuprofen.
Frequency and Timing	The medicine is applied 3 - 4 times daily, with a minimum interval of 4 hours between applications.
Age-group rules	The gel formulation is for use in adolescents 14 years of age and older.
Course Duration	Use is generally short-term. If symptoms persist or worsen after 10 - 14 days, the usage should be reviewed.

Procedural Structure

The procedure involves gently massaging the measured strip of cream or gel into the affected area until it is fully absorbed by the skin. The product is for external use and is not used in combination with an occlusive dressing or bandage. To prevent unintended exposure, hands are washed immediately following each application, unless the hands are the site of treatment. This regimen defines a time-limited course of use, with set parameters on the frequency and total amount of Ibuprofen applied daily.

Research Evidence / Overview of Studies for Dolgit (Topical Ibuprofen)

A substantial part of the evidence for topical ibuprofen formulations, which includes the active ingredient in Dolgit, is derived from short-term, placebo-controlled Randomized Controlled Trials (RCTs) and systematic reviews. This research base has been used in studies examining the symptom measurements in adults experiencing conditions associated with acute or disruptive episodes, such as muscle strains, sprains, or trauma from sports injuries. Researchers monitored patient-reported outcomes describing perceived discomfort, primarily focusing on measurements of change in pain intensity and functional limitation scores during the defined study period.

Systematic reviews that combined data from many of these trials described the patterns of symptom measurements observed in the study populations, particularly outcomes linked to inflammatory or irritative states during the short-term course of application (typically le 7 days). Follow-up durations were limited, meaning research exploring short-term symptom changes does not provide extensive insight into longer-term outcomes related to physical discomfort or functional change. Comparative evidence is lacking; there is limited information to reliably compare topical Ibuprofen directly against every other individual type of topical pain reliever in the research.

Topical ibuprofen was also observed in studies relevant to managing symptoms in localized mild to moderate osteoarthritis, primarily affecting the hand or knee joints. These studies involved medium-term RCTs, often lasting between 6 and 12 weeks, which monitored physiological strain or stress and outcomes reflecting daily functioning or activity level in adult populations. Findings describe patterns observed related to outcomes describing episodic or acute changes in pain. A notable limitation is that a substantial response was also observed in the placebo groups in research exploring chronic conditions.

Long-term effects are not fully established beyond the 12-week trial duration. Data for certain groups remain insufficient, and specific studies examining responses in children or adolescents are limited.

Key Studies & References

1. Topical NSAIDs for acute pain: a meta-analysis (2004)
2. Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs (1998)

How to Store and Dispose of Dolgit?

The official storage conditions for this Ibuprofen topical cream or gel are defined to maintain its quality and efficacy.

Storage Requirement	Regulatory Mandate
Temperature	Store below 25 C (77 F); must not be frozen.
Protection	Keep the product out of direct sunlight.
Safety	Store strictly out of the sight and reach of children.

The medicine is generally stable until its labeled expiration date when kept at the correct room temperature.

Official Disposal Rules

This product is not classified as one of the few medicines that must be flushed. The officially sanctioned methods for disposal include using a community drug take-back program or utilizing a prepaid drug mail-back envelope. If these options are unavailable, the medicine may be disposed of in the household trash only after being mixed with an undesirable substance, such as dirt or used coffee grounds, and then placed in a sealed container or bag. All personal information on the original container must be scratched out before discarding.